Podcast appearances and mentions of Richard M Eglen

In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the use of cellular assays and here we debate the advantages and disadvantages of single-cell versus 3D multi-cell analyses. The phenotypic screening of novel drug candidates determines whether a small molecule (or biologic) exerts the desired pharmacology, either in vitro (isolated cells, organoids, tissues) or in vivo. This functional approach is ‘unbiased’ given that the molecular target, and therefore molecular mechanism of action (MMOA), is only determined following lead identification and preclinical optimisation. By Dr Richard M. Eglen If you'd like to view the original article then follow the link below: https://www.ddw-online.com/screening/p323285-optimising-phenotypic-screening-single-cell-analysis-versus-3d-multicell-analysis.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/136776/(5)-optimising-phenotypic-screening.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

In this episode, we examine the use of 3D organoid cell culture systems as applied to cancer research and the development of novel anti-oncologic drugs. Collectively, this transition from 3D spheroid culture to organoid culture allows researchers to generate multiple organ-specific cell types, resulting in cell architectures that more closely resemble the human tissue microenvironment. Furthermore, researchers are generating organoid cultures that are increasingly complex and more phenotypically relevant and, as a result, optimal models are being established to better understand patient-specific tumour proliferation and invasion patterns. By Dr Amanda Linkous, Hilary Sherman, Iris Li and Dr Richard M. Eglen If you'd like to view the original article then follow the link below: https://www.ddw-online.com/drug-discovery/p322919-3d-organoid-cell-culture-optimising-disease-models-for-research-and-drug-discovery.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/136065/(5)-three-dimensional-organoid.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when drug candidates have already progressed along the development pipeline to clinical trial. Advances in three-dimensional (3D) cell culture systems are helping address the above challenges and improve the likelihood of success for pipeline assets. From disease modelling and validation of novel targets to screening for safety and efficacy, 3D cell cultures offer the exciting potential for the development of novel medicines and increased productivity. This episode describes the benefit of 3D cell culture on the drug discovery workflow, with a focus on lead optimisation in which compounds are assessed for their potential metabolic liability and off-target toxicities. The powerful combination of human-induced pluripotent stem cells (HiPSCs) and 3D cell culture systems are also highlighted. Original article by Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos If you'd like to view the original article then follow the link below: https://www.ddw-online.com/drug-discovery/p322782-optimising-clinical-leads:-increasing-drug-discovery-success-with-3d-cell-culture-systems.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/135185/(3)-optimising-clinical-leads.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

SLAS Technology 24.1 February 2019Guest Editor Richard M. Eglen of Corning Life Sciences (Tewksbury, MA, USA) talks about a new collection of reviews and original research reports that illustrate how the combination of human iPS cells and 3D cell culture technology provide powerful new approaches to the development of novel and more effective therapies. Free access to the published collection is sponsored by Corning Life Sciences.

Guest Editor Richard M. Eglen of Corning Life Sciences (Tewksbury, MA, USA) talks about a new collection of reviews and original research reports that illustrate how the combination of human iPS cells and 3D cell culture technology provide powerful new approaches to the development of novel and more effective therapies. Free access to the published collection is sponsored by Corning Life Sciences.